Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06868485 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Wayshine Biopharm.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 18
- Study locations
NCT06868485 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Wayshine Biopharm. The registered enrollment target is 40 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 18 study locations across 16 states.
The verdict
NCT06868485, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Wayshine Biopharm.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal Growth Factor Receptor Gene.
Conditions Studied
Interventions
- DRUG WSD0922-FU Tablets, Dose level A
- DRUG WSD0922-FU Tablets, Dose level B
Study Locations (18)
Shanghai Municipality
- Shanghai East hospital - Shanghai
- Shanghai Pulmonary Hospital - Shanghai
Nouvelle-Aquitaine
- Centre Hospitalier Universitaire CHU De Limoges - Limoges
- CHU Bordeaux - Centre Francois Magendie - Pessac
California
- FOMAT Oncology - Oxnard
Florida
- Cleveland Clinic Weston Hospital - Weston
Michigan
- Karmanos Cancer Institute - Detroit
New Jersey
- Hackensack Meridian Health-Southern Ocean Medical Center - Manahawkin
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06868485
The ClinicalTrials.gov registry entry for NCT06868485 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Wayshine Biopharm, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which WSD0922-FU Tablets, Dose level A is the first listed.
NCT06868485 reports 18 study locations spanning 16 distinct geographic areas - top geographies include Shanghai Municipality, Nouvelle-Aquitaine, California.
Frequently Asked Questions
What is clinical trial NCT06868485 about?
NCT06868485 is a clinical study titled "A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer". This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal Growth Factor Recep...
What is the current status of trial NCT06868485?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-08-18. Estimated completion is 2027-12-31.
What conditions does trial NCT06868485 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06868485?
The interventions under investigation include: WSD0922-FU Tablets, Dose level A (DRUG), WSD0922-FU Tablets, Dose level B (DRUG).
Who is sponsoring clinical trial NCT06868485?
This trial is sponsored by Wayshine Biopharm, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06868485 being conducted?
This trial has 18 study locations across California, Florida, Michigan, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.